Grandparents sit with their grandchild on stones by the riverside.

Costs

What does health insurance pay?

Which lung cancer medicines are on the public health insurance lists, what for, and how to get the treatment. For Serbia, Montenegro, Albania, Bosnia and Herzegovina, North Macedonia and Kosovo.

  • 8 min read
  • Updated 19 November 2026

Most important in brief

  • Serbia and Montenegro pay for the main EGFR and ALK tablets and immunotherapy, with precise conditions.
  • For KRAS G12C, RET, MET, NTRK and HER2, no medicine is on the list in any country of the region.
  • In Serbia and Montenegro, treatment starts on the proposal of a team of doctors at named hospitals.
  • For Kosovo and Republika Srpska there is no publicly checkable list.
  • “Not on the list” does not mean “never possible”. Ask your care team.

What is paid in your country

Which medicines are on the public health insurance list, by test result. We only state what a public source confirms, with date and link. Whether a medicine applies to you is decided by your care team with the health insurance fund.

Serbia

Lists B and C of the RFZO health insurance fund, valid from 11 July 2026 · List C (PDF), List B (PDF) · checked on 16 November 2026

Test resultMedicineWhat for (simplified)
EGFR
osimertinib
First treatment for advanced NSCLC with an EGFR mutation; with T790M after an earlier EGFR tablet; after complete surgery (stage IB–IIIA, exon 19 or L858R).
EGFR
gefitinib, erlotinib, afatinib
First treatment, stage IIIb/IV, good general condition. Erlotinib also later in adenocarcinoma.
ALK
alectinib, brigatinib
First treatment for advanced ALK-positive NSCLC.
no EGFR or ALK
pembrolizumab
First treatment: alone if PD-L1 is 50% or more, with chemotherapy if PD-L1 is lower. A few cycles first, then continued only if it works.
no EGFR or ALK
atezolizumab
First treatment alone if PD-L1 is high, or with chemotherapy; also after chemotherapy.
Chemotherapy
carboplatin, cisplatin, docetaxel, paclitaxel, gemcitabine, vinorelbine, pemetrexed
Lists B and C. Everything on these lists is fully paid by the fund.

How to get the treatment

Three doctors from one of the hospitals below propose the treatment, and the RFZO commission approves it. The list names these hospitals:

  • Institut za onkologiju i radiologiju Srbije (Beograd)
  • Klinika za pulmologiju, UKC Srbije (Beograd)
  • KBC Bežanijska kosa (Beograd)
  • Vojnomedicinska akademija (Beograd)
  • Institut za plućne bolesti Vojvodine (Sremska Kamenica)
  • Klinika za plućne bolesti, UKC Niš
  • UKC Kragujevac

Not on the list

Lorlatinib, crizotinib and durvalumab; no medicine against KRAS G12C, ROS1, RET, MET, NTRK or HER2. Dabrafenib and trametinib are listed for melanoma only.

What is not publicly known

A new regulation from July 2026 may come with newer tables. Whether biomarker tests are always paid is not stated in these lists.

Montenegro

Medicines list of the FZOCG health insurance fund, October 2026 · List (PDF), all versions · checked on 16 November 2026

Test resultMedicineWhat for (simplified)
EGFR
osimertinib
First treatment with an EGFR mutation; with T790M; after complete surgery (stage IB–IIIA), up to 36 months.
EGFR
gefitinib
Advanced NSCLC with an EGFR mutation.
ALK
alectinib, brigatinib
First treatment or after crizotinib.
ALK
lorlatinib
First treatment or after earlier ALK tablets.
ALK, ROS1
crizotinib
For ALK (first treatment or later) and for ROS1.
no EGFR or ALK
pembrolizumab
First treatment: alone if PD-L1 is 50% or more, with chemotherapy if PD-L1 is lower. A few cycles first, then continued only if it works.
no EGFR or ALK
atezolizumab
First treatment alone if PD-L1 is high, or with chemotherapy; also after chemotherapy.
Stage III
durvalumab
After chemoradiotherapy for inoperable stage III, PD-L1 1% or more, up to 12 months.
Chemotherapy
carboplatin, cisplatin, docetaxel, paclitaxel, gemcitabine, vinorelbine, pemetrexed
On the list.

How to get the treatment

A tumour board proposes the treatment. Usually two cycles are approved first, then the effect is checked. The list names these tumour boards:

  • Klinički centar Crne Gore, Klinika za onkologiju i radioterapiju (Podgorica)
  • Opšta bolnica Bijelo Polje
  • Specijalna bolnica za plućne bolesti Brezovik (Nikšić)

Not on the list

Afatinib, erlotinib, amivantamab; no medicine against KRAS G12C, RET, MET or NTRK. Dabrafenib and trametinib are listed for melanoma only.

Albania

List of the FSDKSH health insurance fund, decision no. 324 of 6 May 2026 · Official Gazette no. 100/2026 (PDF) · checked on 16 November 2026

Cancer medicines are on List I and are dispensed by hospital pharmacies, 90 to 100 percent paid. The 2026 list includes:

  • EGFR: osimertinib
  • ALK: alectinib, lorlatinib
  • BRAF V600E: dabrafenib, trametinib
  • Immunotherapy: pembrolizumab, nivolumab, ipilimumab, atezolizumab

The list does not say for which disease a medicine is paid. Your care team clarifies with the fund whether it applies to you.

Not on the list

Chemotherapy, older EGFR tablets, brigatinib, crizotinib, durvalumab, and no medicine against KRAS G12C, ROS1, RET, MET, NTRK or HER2.

What is not publicly known

How hospitals provide chemotherapy and who applies for a treatment is not publicly described. Ask your care team.

Bosnia and Herzegovina

Federation of Bosnia and Herzegovina

Solidarity Fund list (version 47/19, last amended by 76/26) · List (PDF), September 2026 update · checked on 19 November 2026

Hospital cancer medicines are paid by the Solidarity Fund, not the regular medicines list. The list includes standard chemotherapy, erlotinib, crizotinib, alectinib, nivolumab, pembrolizumab, atezolizumab and dabrafenib with trametinib (explicitly as first treatment for advanced NSCLC). Since September 2026 the list names lung cancer explicitly for pembrolizumab and atezolizumab: both as a first treatment alone or with chemotherapy and after complete surgery, pembrolizumab also before surgery, and atezolizumab also for extensive-stage small cell lung cancer.

Not on the list

Osimertinib, lorlatinib, brigatinib, durvalumab, and no medicine against KRAS G12C, RET, MET, NTRK or HER2.

Republika Srpska

The Republika Srpska health insurance fund only publishes its pharmacy lists. Hospital cancer medicines run through a separate list that is not public. Ask your care team or the fund. Fund lists

North Macedonia

FZOM health insurance medicines list, overview of 7 August 2026 (list B, hospital) · FZOM list · checked on 18 November 2026

MedicineWhat for (simplified)
cisplatin, carboplatin, etoposide
On the list.
gemcitabine
First treatment for NSCLC together with cisplatin, 3 to 6 cycles.
paclitaxel
First treatment for NSCLC together with cisplatin, up to 4 cycles.
docetaxel
First treatment for NSCLC together with cisplatin, 3 to 6 cycles; as second treatment in stage III or IV in good general condition, up to 4 cycles.

Not on the list

Pemetrexed, vinorelbine, all targeted tablets (EGFR, ALK and others) and immunotherapy. Whether they are paid through other state programmes is not stated in this list.

Kosovo

Which cancer medicines the state provides in Kosovo is currently not publicly available. Public hospitals dispense medicines from the essential medicines list, which the Ministry of Health is revising.

According to the Ministry price list, these are among the medicines authorised in Kosovo: osimertinib, erlotinib, alectinib, lorlatinib, crizotinib, pembrolizumab, nivolumab, atezolizumab, durvalumab. Authorised does not mean paid. Ask the oncology clinic what you have to pay yourself. Price list

All countries compared

Show comparison table

Which medicines are on the public lists, by test result and country. Checked on 16 November 2026. Simplified, not a ranking.

Test resultSerbiaMontenegroAlbaniaBosnia and Herzegovina
EGFR, first treatment
osimertinib, gefitinib, erlotinib, afatinib
osimertinib, gefitinib
osimertinib¹
erlotinib²
EGFR, after surgery
osimertinib
osimertinib
osimertinib¹
not on the list
ALK
alectinib, brigatinib
alectinib, brigatinib, lorlatinib, crizotinib
alectinib, lorlatinib¹
alectinib, crizotinib²
ROS1
not on the list
crizotinib
not on the list
crizotinib²
KRAS G12C
not on the list
not on the list
not on the list
not on the list
BRAF V600E
melanoma only
melanoma only
dabrafenib, trametinib¹
dabrafenib, trametinib
RET, MET, NTRK, HER2
not on the list
not on the list
not on the list
not on the list
Immunotherapy, first treatment
pembrolizumab, atezolizumab
pembrolizumab, atezolizumab
pembrolizumab, nivolumab, ipilimumab, atezolizumab¹
pembrolizumab, nivolumab, atezolizumab²
Stage III after chemoradiotherapy
not on the list
durvalumab
not on the list
not on the list
Chemotherapy
yes
yes
not on the list³
yes

¹ Albania: the medicine is on the health insurance list. The list does not say for which disease it is paid.

² Federation of Bosnia and Herzegovina: on the Solidarity Fund list; the indication cannot be read reliably from the published list.

³ Albania: chemotherapy is not on the reimbursement list. How hospitals provide it is not publicly described.

“Not on the list” does not mean a medicine is never given. It only means it is not on this public list.

For Kosovo and Republika Srpska there is no publicly checkable list. More above for each country. What your test result means: Tests.

What to ask

  • Why ask?

    A medicine can be on the list but only paid for in certain situations.

  • Why ask?

    Then you can plan the start of treatment better.

  • Why ask?

    Without the test there is no basis for targeted treatments.

  • Why ask?

    Knowing the costs avoids surprises.

  • Why ask?

    Sometimes there are exceptions, support programmes or a study.

  • Why ask?

    Many hospitals have social services who know the applications.

Sources

  1. RFZO: Lista C, primena od 11.07.2026
  2. RFZO: Lista B, primena od 11.07.2026
  3. FZOCG: Lista ljekova, oktobar 2026
  4. Fletorja Zyrtare 100/2026, VKM nr. 324, 6.5.2026
  5. FBiH: Lista lijekova Fonda solidarnosti 47/19
  6. Službene novine FBiH 76/26, 25.09.2026
  7. FZO Republike Srpske: liste lijekova
  8. FZOM: Листа на лекови
  9. Ministria e Shëndetësisë: lista e çmimeve 1.15

All sources last checked on 12 November 2026, unless another date is given.